| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51b7f64f380c538d4b6aa024f05455da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e22c73f960cad34b47139424c9e1f76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661c68977a99ccd5a68ea29d1b870a1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ef1659a68bba8cc1df17e2d955ff67b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25a7031cde5cefa9e3c756d0bedc2001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e96a7912a4e01334aca3ffd3babe863 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 |
| filingDate |
2015-10-27^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5173a7c4ef906db981cac65abdb4dfc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9df4fc46cca898d919eac5a6031eb1d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dffe244095323bc08259e223e6f980d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d922f0106c72a38d586610b6d5dc0db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6aedca7108ca96fdbf8c3cf57f077a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6775a957367c9f439a9946f4592f3e9d |
| publicationDate |
2016-05-06^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016069517-A1 |
| titleOfInvention |
Piperidine isoxazole and isothiazole orexin receptor antagonists |
| abstract |
The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10526336-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10308645-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10435398-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9994570-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9987255-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10017504-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10000499-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10010539-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10011595-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9938276-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9920038-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10227336-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10214535-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10239838-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10150751-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10155750-B2 |
| priorityDate |
2014-10-30^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |